To assess the durability of pathway suppression by inhibitor treatment, we treated nf1/pten-mutant-melanoma recipients with the inhibitors for 6 days, then analyzed the tumors after 4 days in the absence of the drugs. The gene discussed is NF1; the disease is melanoma.